R 5-Tropic Strains of HIV-1 Macrophages and Lymphocytes with Primary Normal Human IgG Block Infection of Antibodies to C-C Chemokine Receptor 5 in Kaveri and
暂无分享,去创建一个
S. Kaveri | M. Kazatchkine | R. Longhi | H. Hocini | A. Amara | A. Beretta | V. Donkova | N. Haeffner‐cavaillon | Caroline Quillent-Grégoire | S. Rose
[1] G. Fields,et al. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.
[2] S. Kaveri,et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.
[3] L. Lopalco,et al. CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro1 , 2000, The Journal of Immunology.
[4] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[5] R. Zinkernagel,et al. Control of early viral and bacterial distribution and disease by natural antibodies. , 1999, Science.
[6] D. Richman,et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.
[7] J. Silver,et al. Positive selection of natural autoreactive B cells. , 1999, Science.
[8] S. Kaveri,et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). , 1999, Blood.
[9] William C. Olson,et al. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.
[10] J. Wakefield,et al. Vpx is required for dissemination and pathogenesis of SIVSM PBj: Evidence of macrophage-dependent viral amplification , 1998, Nature Medicine.
[11] B. Walker,et al. Acute human immunodeficiency virus type 1 infection. , 1998, The New England journal of medicine.
[12] A. Coutinho,et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. , 1998, Journal of immunological methods.
[13] J. Reece,et al. HIV-1 Selection by Epidermal Dendritic Cells during Transmission across Human Skin , 1998, The Journal of experimental medicine.
[14] K. Bendtzen,et al. High-avidity autoantibodies to cytokines. , 1998, Immunology today.
[15] D R Burton,et al. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Koup,et al. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. , 1998, AIDS research and human retroviruses.
[17] Luc Montagnier,et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene , 1998, The Lancet.
[18] A. Trkola,et al. Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.
[19] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[20] Nancy Sullivan,et al. CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.
[21] R. Royce,et al. Sexual transmission of HIV. , 1997, The New England journal of medicine.
[22] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[23] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[24] John P. Moore,et al. Perspective: Research Highlights at the Aaron Diamond AIDS Research Center: The β-Chemokines, HIV Type 1 Second Receptors, and Exposed Uninfected Persons , 1996 .
[25] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[26] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[27] S. Kaveri,et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. , 1996, The Journal of clinical investigation.
[28] D. Klatzmann,et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). , 1994, Therapeutic immunology.
[29] J. Cairns,et al. Chemokines and HIV-1 second receptors: The therapeutic connection , 1998, Nature Medicine.
[30] J. Moore,et al. The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. , 1996, AIDS research and human retroviruses.
[31] A. Coutinho,et al. Natural autoantibodies. , 1995, Current opinion in immunology.
[32] S. Avrameas,et al. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. , 1991, Immunology today.